BioCentury
ARTICLE | Company News

GlaxoSmithKline sales and marketing update

May 23, 2016 7:00 AM UTC

The U.K.’s NICE issued a final appraisal determination (FAD) recommending Benlysta belimumab from GlaxoSmithKline as add-on therapy in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity -- its approved indication. The list price for a 120 mg vial of the subcutaneous human mAb against BLyS (BAFF) is L121.50 ($174.41); the list price for a 400 mg vial is L405 ($581.38). The recommended dose is 10 mg/kg on days 0, 14 and 28 and every four weeks thereafter. ...